Amsterdam: Europe’s medicines regulator has waved through a fresh clutch of medicine approvals, recommending twelve new products for use across the bloc after its scientific committee wrapped up its July meeting.

The Committee for Medicinal Products for Human Use, the panel that advises the European Medicines Agency, endorsed the batch during its 20 to 23 July session. The European Commission now turns those opinions into binding marketing authorisations, and national health systems typically follow within weeks.

Three of the recommendations tackle high cholesterol, a driver of heart attacks and strokes across the continent. Doctors will be able to prescribe Lyrokaul, a monthly injection that patients give themselves, alongside two daily tablets, Evlarco and Ubeslo. Regulators hope the wider menu nudges more people toward treatment they can actually stick with.

The committee also backed Susvimo, a refillable implant that a surgeon places inside the eye to treat wet age-related macular degeneration, a leading cause of sight loss in older Europeans. It marks the first device of its kind to reach the EU market, and it spares patients the frequent injections that current therapies demand.

Beyond the new products, the panel widened the approved uses of eight medicines that already circulate in Europe, including several cancer and inflammatory-disease treatments. These extensions rarely grab headlines, yet they often matter more to patients than brand-new launches because they stretch proven drugs to fresh groups who had run out of options.

The agency publishes each verdict in its meeting highlights, and campaigners read them closely. You can follow the full list through the regulator’s own meeting summary, which spells out the conditions attached to every recommendation.

Speed remains the sore point. Industry groups argue that Europe still trails the United States in getting innovative therapies to patients, and they want the Commission to press ahead with its long-promised overhaul of pharmaceutical law. Patient organisations counter that faster approvals mean little if national payers then haggle for months over price before a drug reaches a single pharmacy.

The regulator insists it has tightened its timelines without cutting corners on safety, and it points to the steady monthly flow of recommendations as proof. Critics reply that a healthy pipeline at the assessment stage tells only half the story, since access still splinters along national lines once the science is settled.

For now, the July verdicts hand clinicians a broader toolkit, particularly for heart health and vision. Whether patients feel the benefit soon will depend less on the committee in Amsterdam and more on the pricing talks that unfold, capital by capital, in the months ahead.